Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Ziconotide (Prialt®) for the intrathecal treatment of severe, chronic pain. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0708. 2008 Authors' conclusions Ziconotide (Prialt) is not recommended for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.
Key factor influencing the recommendation:
The case for cost effectiveness of ziconotide (Prialt) has not been proven. Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Non-Narcotic; Chronic Disease; Humans; Injections, Spinal; Pain; omega-Conotoxins Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000442 Date abstract record published 08/08/2012 |